Masimo (NASDAQ:MASI) updated its FY 2021
After-Hours earnings guidance on Wednesday. The company provided earnings per share guidance of 3.80-3.80 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.82. The company issued revenue guidance of $1.2-1.2 billion, compared to the consensus revenue estimate of $1.17 billion.Masimo also updated its FY 2020
After-Hours guidance to 3.46 EPS.
A number of equities research analysts recently weighed in on the company. Stifel Nicolaus upped their price objective on Masimo from $255.00 to $276.00 and gave the company a buy rating in a report on Wednesday, October 28th. BidaskClub raised Masimo from a buy rating to a strong-buy rating in a report on Friday, November 6th. Needham & Company LLC reissued a hold rating on shares of Masimo in a report on Tuesday, October 6th. Raymond James increased their target price on Masimo from $250.00 to $275.00 and gave the stock an outperform rating in a report on Wednesday, October 28th. Finally, Zacks Investment Research lowered Masimo from a buy rating to a hold rating and set a $258.00 target price on the stock. in a report on Thursday, October 8th. Four investment analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company’s stock. Masimo presently has an average rating of Buy and an average target price of $260.71.
Masimo stock traded down $5.36 during trading hours on Thursday, hitting $270.91. The stock had a trading volume of 1,150 shares, compared to its average volume of 247,213. The stock has a market cap of $14.91 billion, a price-to-earnings ratio of 71.76, a P/E/G ratio of 3.90 and a beta of 0.87. Masimo has a one year low of $143.90 and a one year high of $284.86. The business’s 50 day simple moving average is $266.33 and its 200-day simple moving average is $238.93.
In related news, Director Craig B. Reynolds sold 10,000 shares of the stock in a transaction on Monday, January 11th. The shares were sold at an average price of $279.74, for a total transaction of $2,797,400.00. Following the transaction, the director now directly owns 14,300 shares of the company’s stock, valued at $4,000,282. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Joe E. Kiani sold 55,971 shares of the stock in a transaction on Tuesday, December 8th. The stock was sold at an average price of $270.68, for a total transaction of $15,150,230.28. Following the transaction, the chief executive officer now directly owns 215,212 shares in the company, valued at $58,253,584.16. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 191,781 shares of company stock worth $50,364,663. Insiders own 11.50% of the company’s stock.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies and hospital automation solutions worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Story: Should I follow buy, hold and sell recommendations?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.